Armata Pharmaceuticals (ARMP) Income from Continuing Operations: 2013-2024
Historic Income from Continuing Operations for Armata Pharmaceuticals (ARMP) over the last 12 years, with Dec 2024 value amounting to -$53.2 million.
- Armata Pharmaceuticals' Income from Continuing Operations rose 53.19% to -$1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$15.9 million, marking a year-over-year decrease of 63.16%. This contributed to the annual value of -$53.2 million for FY2024, which is 22.71% down from last year.
- Latest data reveals that Armata Pharmaceuticals reported Income from Continuing Operations of -$53.2 million as of FY2024, which was down 22.71% from -$43.3 million recorded in FY2023.
- In the past 5 years, Armata Pharmaceuticals' Income from Continuing Operations registered a high of -$22.2 million during FY2020, and its lowest value of -$53.2 million during FY2024.
- Moreover, its 3-year median value for Income from Continuing Operations was -$43.3 million (2023), whereas its average is -$44.5 million.
- Data for Armata Pharmaceuticals' Income from Continuing Operations shows a maximum YoY plummeted of 54.35% (in 2022) over the last 5 years.
- Yearly analysis of 5 years shows Armata Pharmaceuticals' Income from Continuing Operations stood at -$22.2 million in 2020, then fell by 7.80% to -$23.9 million in 2021, then slumped by 54.35% to -$36.9 million in 2022, then declined by 17.39% to -$43.3 million in 2023, then fell by 22.71% to -$53.2 million in 2024.